FDA Pushes Drugmakers to Report Missing Clinical Trial Results

The Food and Drug Administration sent reminder letters to more than 2,200 companies and researchers regarding over 3,000 registered clinical trials with unreported results, after an internal analysis found nearly 30% of studies highly likely subject to mandatory reporting requirements failed to submit data. The agency may impose fines on non-compliant entities as part of new enforcement efforts to improve transparency in the federal clinical trial database. Researchers argue that missing trial data prevents duplication of results, inhibits understanding of how medicines work, and adversely affects treatment decisions and healthcare costs. The enforcement campaign covers both privately and publicly funded trials.

FDA enforcement action on unreported clinical trial results

• ▪The Food and Drug Administration may impose fines on companies and researchers who fail to report clinical trial results to the federal government database
• ▪The Food and Drug Administration sent letters to companies and researchers associated with more than 3,000 registered trials
• ▪An internal Food and Drug Administration analysis found results were not submitted for nearly 30% of studies highly likely to fall under mandatory reporting requirements
• ▪The Food and Drug Administration sent reminder letters to more than 2,200 companies and researchers regarding required clinical trial results reporting

Impact on medical research transparency and healthcare decisions

• ▪Researchers have argued that without access to specific clinical trial data, trial results cannot be easily duplicated
• ▪Researchers contend that lack of access to clinical trial data can adversely affect treatment decisions
• ▪Lack of access to specific clinical trial data inhibits greater understanding of how medicines might work, according to researchers

Perspective of Researchers and transparency advocates

• ▪Missing clinical trial data creates information gaps that compromise physicians' ability to make evidence-based treatment choices
• ▪Unreported clinical trial results prevent independent verification of pharmaceutical research findings
• ▪Incomplete clinical trial reporting may hide safety signals or efficacy limitations that affect patient outcomes

Perspective of Pharmaceutical companies and research sponsors

• ▪More than 2,200 pharmaceutical companies and researchers received Food and Drug Administration warning letters about overdue clinical trial results
• ▪Clinical trial sponsors risk federal fines for failing to submit results to government databases within required timeframes

Perspective of Food and Drug Administration

• ▪The Food and Drug Administration's enforcement campaign targets over 3,000 registered clinical trials with missing results submissions
• ▪The Food and Drug Administration is transitioning from passive monitoring to active enforcement of clinical trial reporting obligations
• ▪The Food and Drug Administration identified systematic non-compliance affecting approximately 30% of trials subject to mandatory reporting rules